Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05366166 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab Plus Olaparib in LA-HNSCC

A Phase 2 study of Squamous Cell Carcinoma of Head and Neck, sponsored by UNC Lineberger Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
45
Enrollment target
4
Study locations

NCT05366166 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 45 participants, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (73% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05366166, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by UNC Lineberger Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.

Conditions Studied

Squamous Cell Carcinoma of Head and Neck

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Cisplatin
  • DRUG Olaparib
  • RADIATION IMRT (intensity modulated radiation therapy)

Study Locations (4)

Indiana

  • Indiana University Simon Comprehensive Cancer Center - Indianapolis

Kentucky

  • University of Louisville, Brown Cancer Center - Louisville

North Carolina

  • UNC Lineberger - Chapel Hill

South Carolina

  • Medical University of South Carolina (MUSC) - Charleston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2022-09-02
Est. Completion 2030-11-21
Phase Phase 2

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05366166

The ClinicalTrials.gov registry entry for NCT05366166 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (73% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05366166 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Kentucky, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05366166 about?

NCT05366166 is a clinical study titled "Pembrolizumab Plus Olaparib in LA-HNSCC". The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are appro...

What is the current status of trial NCT05366166?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2022-09-02. Estimated completion is 2030-11-21.

What conditions does trial NCT05366166 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT05366166?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Olaparib (DRUG), IMRT (intensity modulated radiation therapy) (RADIATION).

Who is sponsoring clinical trial NCT05366166?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05366166 being conducted?

This trial has 4 study locations across Indiana, Kentucky, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.